Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ⅲ, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of IBI112 in Different Dose Regimens for the Treatment of Subjects With Moderate-to-severe Plaque Psoriasis

Next Previous
Trial Profile

A Phase Ⅲ, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of IBI112 in Different Dose Regimens for the Treatment of Subjects With Moderate-to-severe Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Picankibart (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms CLEAR; CLEAR-1
  • Sponsors Innovent Biologics

Most Recent Events

  • 28 Nov 2025 Results presented in an Innovent Biologics media release
  • 28 Nov 2025 According to an Innovent Biologics media release, company announces that China's National Medical Products Administration (NMPA) has approved PECONDLE (picankibart injection), for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systematic therapy.
  • 26 Sep 2025 According to an Innovent Biologics media release, data from this trial presented at the 2025 European Society of Dermatology (EADV) Annual Meeting

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top